Curative Biotechnology Inc (CUBT) - Total Assets
Based on the latest financial reports, Curative Biotechnology Inc (CUBT) holds total assets worth $2.29 Million USD as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Curative Biotechnology Inc shareholders equity for net asset value and shareholders' equity analysis.
Curative Biotechnology Inc - Total Assets Trend (2013–2024)
This chart illustrates how Curative Biotechnology Inc's total assets have evolved over time, based on quarterly financial data.
Curative Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Curative Biotechnology Inc's total assets of $2.29 Million consist of 9.8% current assets and 90.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0.9% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.35 Million | 62.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Curative Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see CUBT stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Curative Biotechnology Inc's current assets represent 9.8% of total assets in 2024, a decrease from 50.5% in 2013.
- Cash Position: Cash and equivalents constituted 0.9% of total assets in 2024, down from 1.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 29.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 62.3% of total assets.
Curative Biotechnology Inc Competitors by Total Assets
Key competitors of Curative Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GlycoMimetics Inc
NASDAQ:GLYC
|
USA | $5.99 Billion |
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
USA | $19.62 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $584.09 Million |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Curative Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.05 | 0.05 | 0.00 |
| Quick Ratio | 0.05 | 0.05 | 0.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-6.92 Million | $-5.58 Million | $-32.18K |
Curative Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Curative Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 3.22 |
| Asset Growth Rate (YoY) | -16.9% |
| Total Assets | $2.16 Million |
| Market Capitalization | $6.97 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Curative Biotechnology Inc's assets at a significant premium (3.22x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Curative Biotechnology Inc's assets decreased by 16.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Curative Biotechnology Inc (2013–2024)
The table below shows the annual total assets of Curative Biotechnology Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $2.16 Million | -16.89% |
| 2023-12-31 | $2.60 Million | +24.60% |
| 2022-12-31 | $2.09 Million | -13.39% |
| 2021-12-31 | $2.41 Million | +6.07% |
| 2020-12-31 | $2.27 Million | +5617.42% |
| 2019-12-31 | $39.77K | -11.76% |
| 2018-12-31 | $45.08K | -23.55% |
| 2017-12-31 | $58.96K | -10.55% |
| 2016-12-31 | $65.91K | -3.32% |
| 2015-12-31 | $68.17K | -63.58% |
| 2014-12-31 | $187.19K | -18.03% |
| 2013-12-31 | $228.38K | -- |
About Curative Biotechnology Inc
Curative Biotechnology, Inc., a biopharmaceutical company, focuses on identifying, in licensing, and developing therapeutic drug candidates for rare disease indications. It develops Metformin Reformulation to treat intermediate dry macular degeneration and geographic atrophy; IMT504, a novel immunotherapy to treat late-stage rabies; and CUBT906, a fully humanized CD56 monoclonal antibody carrying… Read more